Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Even as Biogen weighs strategic options for its biosimilars unit, the group is celebrating an industry first.

Biogen’s version of Roche’s autoimmune drug Actemra has won FDA approval, the company said Friday. The drug becomes the first biosimilar alternative to Actemra to gain an agency nod.